![Heterotypic interactions drive antibody synergy against a malaria vaccine candidate | Nature Communications Heterotypic interactions drive antibody synergy against a malaria vaccine candidate | Nature Communications](https://media.springernature.com/lw685/springer-static/image/art%3A10.1038%2Fs41467-022-28601-4/MediaObjects/41467_2022_28601_Fig6_HTML.png)
Heterotypic interactions drive antibody synergy against a malaria vaccine candidate | Nature Communications
![Heterotypic interactions drive antibody synergy against a malaria vaccine candidate | Nature Communications Heterotypic interactions drive antibody synergy against a malaria vaccine candidate | Nature Communications](https://media.springernature.com/full/springer-static/image/art%3A10.1038%2Fs41467-022-28601-4/MediaObjects/41467_2022_28601_Fig1_HTML.png)
Heterotypic interactions drive antibody synergy against a malaria vaccine candidate | Nature Communications
![Heterotypic interactions drive antibody synergy against a malaria vaccine candidate | Nature Communications Heterotypic interactions drive antibody synergy against a malaria vaccine candidate | Nature Communications](https://media.springernature.com/lw685/springer-static/image/art%3A10.1038%2Fs41467-022-28601-4/MediaObjects/41467_2022_28601_Fig4_HTML.png)
Heterotypic interactions drive antibody synergy against a malaria vaccine candidate | Nature Communications
![Heterotypic interactions drive antibody synergy against a malaria vaccine candidate | Nature Communications Heterotypic interactions drive antibody synergy against a malaria vaccine candidate | Nature Communications](https://media.springernature.com/lw685/springer-static/image/art%3A10.1038%2Fs41467-022-28601-4/MediaObjects/41467_2022_28601_Fig3_HTML.png)
Heterotypic interactions drive antibody synergy against a malaria vaccine candidate | Nature Communications
![Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK - The Lancet Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK - The Lancet](https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/attachment/c0547203-d7c7-4471-bd9b-1440f4613981/gr1_lrg.jpg)
Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK - The Lancet
![Summary of vaccine and/or passive immunization status for the neglected... | Download Scientific Diagram Summary of vaccine and/or passive immunization status for the neglected... | Download Scientific Diagram](https://i1.rgstatic.net/publication/358664588_Heterotypic_interactions_drive_antibody_synergy_against_a_malaria_vaccine_candidate/links/620e5030eb735c508adb108d/largepreview.png)